Founder and CEO
Early Clinical Development
Cellmedica
United Kingdom
Gregg holds an MSc in immunology from Imperial College School of Medicine in London, as well as an MBA from the University of Chicago and a BA in biochemistry from Harvard University.Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in collaboration with a small group of leading clinicians and immunologists who were pioneering this new type of medical treatment.
Immunology, Cell therapy, Biochemistry